Evidence map›Paper›PMID 37108119›Full record

ArticleInternational journal of molecular sciences2023

The oDGal Mouse: A Novel, Physiologically Relevant Rodent Model of Sporadic Alzheimer's Disease.

Wayne Chadwick, Stuart Maudsley, William Hull, Enes Havolli, Eugene Boshoff, Mark D W Hill, Pascal J D Goetghebeur, David C Harrison, Sohaib Nizami, David C Bedford and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Wayne ChadwickTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.ORCID 0000-0003-1465-8180
Stuart MaudsleyReceptor Biology Lab, University of Antwerp, 2000 Antwerp, Belgium.ORCID 0000-0002-1868-184X
William HullWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Centre for Translational Medicine and Therapeutics, Queen Mary University of London, London E1 4NS, UK.ORCID 0000-0001-7666-3853
Enes HavolliTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Eugene BoshoffTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Mark D W HillTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Pascal J D GoetghebeurTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
David C HarrisonTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.ORCID 0009-0005-1642-7791
Sohaib NizamiTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.ORCID 0000-0002-6322-3688
David C BedfordTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Gareth CoopeTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Katia RealTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Christoph ThiemermannWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Centre for Translational Medicine and Therapeutics, Queen Mary University of London, London E1 4NS, UK.ORCID 0000-0003-4228-9722
Peter MaycoxTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Mark CarltonTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Sarah L ColeTakeda Cambridge, 418 Cambridge Science Park, Cambridge CB4 0PZ, UK.
Takeda (United Kingdom) · GBQueen Mary University of London · GBUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sporadic Alzheimer's disease (sAD) represents a serious and growing worldwide economic and healthcare burden. Almost 95% of current AD patients are associated with sAD as opposed to patients presenting with well-characterized genetic mutations that lead to AD predisposition, i.e., familial AD (fAD). Presently, the use of transgenic (

Indexed as

Alzheimer DiseaseCognition DisordersAmyloid beta-PeptidesAnimalsAnimals, Genetically ModifiedDisease Models, AnimalHumansMemoryMiceAmyloid beta-Peptidesadvanced glycation end productsamyloid betacognitive deficitsD-galactoseneurodegenerationoxidative stresssporadic Alzheimer’s disease

Identifiers

PMID37108119
PMCPMC10138655
OpenAlexW4362732943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.